BRIEF-J&J Says New Talvey Plus Darzalex Faspro Data Demonstrate Strength Of Bispecific Combination In Earlier-Line Relapsed Or Refractory Multiple Myeloma

10

June 13 (Reuters) – Johnson & Johnson: * NEW TALVEY® (TALQUETAMAB-TGVS) PLUS DARZALEX FASPRO® (DARATUMUMAB AND HYALURONIDASE-FIHJ) DATA DEMONSTRATE THE STRENGTH OF A BISPECIFIC COMBINATION IN

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)